Lexicon drug shows cardiac and platelet effects in preclinical studies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Wall Street sinks as Nasdaq falls over 2% on AI cost worries
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease
October 21, 2026 8:30 AM EDT-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy --
-- Second preclinical study shows inhibitory effects of sotagliflozin on platelet activity and thrombus formation --
-- Findings underscore differentiated biology associated with dual SGLT1 and SGLT 2 inhibition --
THE WOODLANDS, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) --... More



